IDH1 (mutant R132G) Antibodies

Target Information

The IDH1 gene, located on chromosome 2q34, encodes isocitrate dehydrogenase 1, an enzyme that plays a critical role in the citric acid cycle and cellular metabolism by catalyzing the oxidative decarboxylation of isocitrate to alpha-ketoglutarate. The R132G mutation in IDH1 involves the substitution of glycine for arginine at position 132, a hotspot for mutations in various cancers, most notably in gliomas and acute myeloid leukemia (AML). This mutation results in a neomorphic enzyme activity that reduces alpha-ketoglutarate to D-2-hydroxyglutarate, an oncometabolite that contributes to oncogenesis by altering cellular differentiation and epigenetic regulation through inhibition of alpha-ketoglutarate-dependent dioxygenases. The accumulation of D-2-hydroxyglutarate is a hallmark of IDH1-mutant cancers and serves as a diagnostic biomarker. Targeting mutant IDH1 with specific inhibitors has emerged as a therapeutic strategy, aiming to reverse the metabolic and epigenetic aberrations caused by this mutation and provide clinical benefit in cancers harboring this alteration.

Synonyms

IDH1 R132G; Isocitrate Dehydrogenase 1 (mutant R132G)